51 min
The global pharma leader with an eye on societal impact Molecule to Market: Inside the outsourcing space
-
- Life Sciences
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Enloe, President and CEO at Societal™ CDMO. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
Being at the birth of viral vectors and the-infant gene therapy field in the 90s... but choosing not to be there today.
After a career spent all over the world - he shares his pearls of wisdom of what he’s learnt from a lifetime of international business.
Navigating business confusion and redefining companies from the inside out, while focusing on people and patients.
Being a humble, humane, empathetic leader that does not take himself too seriously... and makes decisions quickly.
Uncertainty around the capital markets and what this means to the CDMO space in terms of potential headwinds.
David has over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing.He was CEO at Ajinomoto Bio-Pharma Services, CEO at Althea CMO and also served as head of Lonza’s Viral Therapeutics Business Unit, which resulted from Lonza’s acquisition of Vivante GMP Solutions. Prior to that, he spent 14 years with a biotech company, Introgen Therapeutics, and played an integral part in taking the company through a successful IPO in 2020.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Enloe, President and CEO at Societal™ CDMO. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
Being at the birth of viral vectors and the-infant gene therapy field in the 90s... but choosing not to be there today.
After a career spent all over the world - he shares his pearls of wisdom of what he’s learnt from a lifetime of international business.
Navigating business confusion and redefining companies from the inside out, while focusing on people and patients.
Being a humble, humane, empathetic leader that does not take himself too seriously... and makes decisions quickly.
Uncertainty around the capital markets and what this means to the CDMO space in terms of potential headwinds.
David has over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing.He was CEO at Ajinomoto Bio-Pharma Services, CEO at Althea CMO and also served as head of Lonza’s Viral Therapeutics Business Unit, which resulted from Lonza’s acquisition of Vivante GMP Solutions. Prior to that, he spent 14 years with a biotech company, Introgen Therapeutics, and played an integral part in taking the company through a successful IPO in 2020.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.
51 min